September 4, 2020 -- The University of Texas MD Anderson Cancer Center and Xencor have entered a strategic collaboration to study investigational treatments for cancers. Together, they will collaborate to design and execute clinical studies with Xencor's X monoclonal antibody (XmAb) drug candidates.
The drug candidates include novel bispecific antibodies and engineered cytokines with a heterodimer Fc domain, which enables rapid design, simplified development, and stable structure. Nine XmAb bispecific antibodies and one engineered cytokine are being evaluated in phase I clinical studies conducted by Xencor and its partners:
- CD3 bispecific antibodies (CD123 x CD3, CD20 x CD3, SSTR2 x CD3) that contain a tumor associated antigen and a second binding domain targeted to CD3, an activating receptor on T cells
- Tumor microenvironment activator bispecific antibodies incorporating Xencor's Xtend technology for increased half-life (XmAb20717, XmAb22841, XmAb23104)
- Cytokines built with Xencor's XmAb bispecific Fc domain for improved potency and Xtend technology for increased half-life (XmAb24306, co-developed with Genetech)
Xencor has committed to funding and supporting these studies over an initial five-year term.
Copyright © 2020 scienceboard.net